Our portfolio companies
We seek to invest in privately held companies with best-in-class management teams to help accelerate their growth.
- INVESTMENT STATUS
- YEAR INVESTED
Synthetic biology company created as a joint venture between Bayer and Ginkgo Bioworks, focused on genetically engineering naturally occurring microbes to improve farmers’ crop yields, crop quality, and cost structure.
Joyn’s assets were acquired by Ginkgo in 2022 in exchange for rights to receive commercialization royalty payments.
|Investment status||Year invested|
As of date June 30, 2023